Pay in 4 interest-free payments of $7.03 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Early-phase clinical trials including a Phase 2 dose-ranging study published in the New England Journal of Medicine (2023) have demonstrated significant potential for weight reduction and metabolic improvement, generating considerable scientific interest
Rapid urbanization, sedentary lifestyles, and changing diets have further escalated the incidence of type 2 diabetes and related metabolic disorders
In addition, the legal landscape surrounding incretin-based therapies is complex
Scarpellini E, Abenavoli L, Cassano V et al (2022) The apparent asymmetrical relationship between small bowel bacterial overgrowth, endotoxemia, and liver steatosis and fibrosis in cirrhotic and non-cirrhotic patients: a single-center pilot study
Prior authorization is the primary access barrier for most Maine patients
US$ 27.74
US$ 22.22
US$ 29.90
